Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilafupα + apatinib + AG chemotherapy as first-line treatment for unresectable pancreatic ductal adenocarcinoma (Phase II, single-arm)
ChiCTR2600129230Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Shanxi Medical University
- Start
- Aug 2026
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib, gemcitabine and paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by First Affiliated Hospital of Shanxi Medical University. Primary endpoint: Progression-free survival (PFS). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
Rivoceranibgemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2600129230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129230.